Influenza - Wiki-CORONA

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
FGF12 and SRPK1	fibroblast growth factor 12	SRSF protein kinase 1	Phase 0 - rapid depolarisation
FGF12 and SRPK2	fibroblast growth factor 12	SRSF protein kinase 2	Phase 0 - rapid depolarisation			Adenine Purvalanol Phosphoaminophosphonic Acid-Adenylate Ester
FGF12 and IKZF1	fibroblast growth factor 12	IKAROS family zinc finger 1	Phase 0 - rapid depolarisation
FGF12 and MAPK8IP2	fibroblast growth factor 12	mitogen-activated protein kinase 8 interacting protein 2	Phase 0 - rapid depolarisation
FGF12 and DPPA2	fibroblast growth factor 12	developmental pluripotency associated 2	Phase 0 - rapid depolarisation
FGF12 and LZTS2	fibroblast growth factor 12	leucine zipper tumor suppressor 2	Phase 0 - rapid depolarisation
FGF12 and NEDD4	fibroblast growth factor 12	NEDD4 E3 ubiquitin protein ligase	Phase 0 - rapid depolarisation	ISG15 antiviral mechanism Downregulation of ERBB4 signaling Regulation of PTEN localization Regulation of PTEN stability and activity Antigen processing: Ubiquitination & Proteasome degradation
FGF12 and NEDD4L	fibroblast growth factor 12	NEDD4 like E3 ubiquitin protein ligase	Phase 0 - rapid depolarisation	Budding and maturation of HIV virion Downregulation of TGF-beta receptor signaling Downregulation of SMAD2/3:SMAD4 transcriptional activity Stimuli-sensing channels Antigen processing: Ubiquitination & Proteasome degradation
FGFR2 and PTPRR	fibroblast growth factor receptor 2	protein tyrosine phosphatase receptor type R	Signaling by FGFR2 amplification mutants Activated point mutants of FGFR2 Signaling by FGFR2 in disease Signaling by FGFR2 IIIa TM Signaling by FGFR2 fusions		Palifermin Thalidomide Heparin Sucrosofate SU4984 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Regorafenib Ponatinib Lenvatinib Nintedanib		Gastric cancer Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
FGFR4 and PTPRR	fibroblast growth factor receptor 4	protein tyrosine phosphatase receptor type R	PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling		Palifermin Heparin Ponatinib Lenvatinib
FHL3 and SPATA8	four and a half LIM domains 3	spermatogenesis associated 8
FKBP1A and TGFB1	FKBP prolyl isomerase 1A	transforming growth factor beta 1	Calcineurin activates NFAT TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGFBR1 LBD Mutants in Cancer	Platelet degranulation Influenza Virus Induced Apoptosis Cell surface interactions at the vascular wall Molecules associated with elastic fibres Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) Syndecan interactions ECM proteoglycans SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer Transcriptional regulation of white adipocyte differentiation UCH proteinases Interleukin-4 and Interleukin-13 signaling RUNX3 regulates CDKN1A transcription Regulation of RUNX3 expression and activity RUNX3 regulates p14-ARF	Pimecrolimus Tacrolimus Sirolimus (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid Gpi-1046 Methyl Methylsulfinylmethyl Sulfide FKB-001 Heptyl-Beta-D-Glucopyranoside L-709,587 (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine 4-Hydroxy-2-Butanone GPI-1485 Myristic acid (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine	Hyaluronidase Hyaluronidase (Human Recombinant)		Graft-versus-host disease Allograft rejection Camurati-Engelmann disease; Progressive diaphyseal dysplasia
FMOD and TGFB1	fibromodulin	transforming growth factor beta 1	Keratan sulfate biosynthesis Keratan sulfate degradation ECM proteoglycans Defective CHST6 causes MCDC1 Defective ST3GAL3 causes MCT12 and EIEE15 Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)	Platelet degranulation Influenza Virus Induced Apoptosis Cell surface interactions at the vascular wall Molecules associated with elastic fibres Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) Syndecan interactions ECM proteoglycans SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer Transcriptional regulation of white adipocyte differentiation UCH proteinases Interleukin-4 and Interleukin-13 signaling RUNX3 regulates CDKN1A transcription Regulation of RUNX3 expression and activity RUNX3 regulates p14-ARF		Hyaluronidase Hyaluronidase (Human Recombinant)		Graft-versus-host disease Allograft rejection Camurati-Engelmann disease; Progressive diaphyseal dysplasia
FN1 and MMP9	fibronectin 1	matrix metallopeptidase 9	Platelet degranulation Degradation of the extracellular matrix Degradation of the extracellular matrix Extracellular matrix organization Fibronectin matrix formation Cell surface interactions at the vascular wall Molecules associated with elastic fibres Integrin cell surface interactions Syndecan interactions Non-integrin membrane-ECM interactions ECM proteoglycans Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MAP2K and MAPK activation Interleukin-4 and Interleukin-13 signaling Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF MET activates PTK2 signaling Post-translational protein phosphorylation Signaling downstream of RAS mutants	Signaling by SCF-KIT Collagen degradation Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Assembly of collagen fibrils and other multimeric structures EPH-ephrin mediated repulsion of cells Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation Extra-nuclear estrogen signaling	Zinc Ocriplasmin	Glutathione Marimastat Minocycline Captopril Glucosamine Zinc 2-Amino-N,3,3-Trimethylbutanamide 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid AE-941 PG-530742 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID		Penile cancer Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
FNTA and TGFB1	farnesyltransferase, CAAX box, alpha	transforming growth factor beta 1	Apoptotic cleavage of cellular proteins Inactivation, recovery and regulation of the phototransduction cascade	Platelet degranulation Influenza Virus Induced Apoptosis Cell surface interactions at the vascular wall Molecules associated with elastic fibres Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) Syndecan interactions ECM proteoglycans SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer Transcriptional regulation of white adipocyte differentiation UCH proteinases Interleukin-4 and Interleukin-13 signaling RUNX3 regulates CDKN1A transcription Regulation of RUNX3 expression and activity RUNX3 regulates p14-ARF	AZD3409 2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE (11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE 4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID FARNESYL DIPHOSPHATE Geranylgeranyl diphosphate ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID 2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE (20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE (20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE	Hyaluronidase Hyaluronidase (Human Recombinant)		Graft-versus-host disease Allograft rejection Camurati-Engelmann disease; Progressive diaphyseal dysplasia
FOS and MITF	Fos proto-oncogene, AP-1 transcription factor subunit	melanocyte inducing transcription factor	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) FCERI mediated MAPK activation Activation of the AP-1 family of transcription factors Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes Estrogen-dependent gene expression NGF-stimulated transcription Estrogen-dependent nuclear events downstream of ESR-membrane signaling	SUMOylation of transcription factors	Pseudoephedrine Nadroparin			Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA) Waardenburg syndrome (WS) Malignant melanoma
G6PC and SNX13	glucose-6-phosphatase catalytic subunit	sorting nexin 13	Glycogen storage disease type Ia (G6PC) Gluconeogenesis FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes				Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
GABRA2 and GABRG2	gamma-aminobutyric acid type A receptor subunit alpha2	gamma-aminobutyric acid type A receptor subunit gamma2	GABA receptor activation GABA receptor activation	Signaling by ERBB4 GABA receptor activation GABA receptor activation	Lorazepam Ethchlorvynol Enflurane Temazepam Temazepam Butabarbital Butalbital Butalbital Topiramate Etomidate Talbutal Talbutal Pentobarbital Pentobarbital Olanzapine Clobazam Meprobamate Meprobamate Eszopiclone Eszopiclone Alprazolam Secobarbital Zolpidem Metharbital Metharbital Chlordiazepoxide Amoxapine Adinazolam Thiopental Clorazepate Acamprosate Midazolam Flurazepam Isoflurane Primidone Primidone Halazepam Halazepam Propofol Diazepam Diazepam Oxazepam Oxazepam Methylphenobarbital Triazolam Triazolam Ethanol Methoxyflurane Ergoloid mesylate Clonazepam Methyprylon Halothane Desflurane Zopiclone Flumazenil Estazolam Estazolam Sevoflurane Quinidine barbiturate Amobarbital Aprobarbital Butethal Heptabarbital Hexobarbital Glutethimide Barbital Barbituric acid derivative Flunitrazepam Bromazepam Clotiazepam Fludiazepam Prazepam Prazepam Quazepam Quazepam Cinolazepam Nitrazepam Prasterone Taurine Pagoclone Ganaxolone Adipiplon Stiripentol Etizolam Thiocolchicoside Lormetazepam	Lorazepam Ethchlorvynol Enflurane Temazepam Temazepam Butabarbital Butalbital Topiramate Etomidate Talbutal Pentobarbital Olanzapine Clobazam Meprobamate Carisoprodol Eszopiclone Alprazolam Zolpidem Metharbital Chlordiazepoxide Amoxapine Adinazolam Clorazepate Acamprosate Midazolam Flurazepam Isoflurane Primidone Halazepam Halazepam Propofol Diazepam Diazepam Oxazepam Oxazepam Triazolam Triazolam Methoxyflurane Ergoloid mesylate Clonazepam Methyprylon Halothane Desflurane Flumazenil Flumazenil Estazolam Estazolam Sevoflurane Ginkgo biloba Glutethimide Flunitrazepam Bromazepam Clotiazepam Fludiazepam Prazepam Prazepam Quazepam Quazepam Cinolazepam Nitrazepam Prasterone Taurine Adipiplon Stiripentol Etizolam Thiocolchicoside Muscimol Lormetazepam		Febrile seizures, including: Febrile convulsions; Generalized epilepsy with febrile seizure plus (GEFS+); Dravet syndrome/ Severe myoclonic epilepsy in infancy (SMEI) Idiopathic generalied epilepsies (IGEs), including: Childhood absence epilepsy (CAE); Juvenile absence epilepsy (JAE); Juvenile myoclonic epilepsy (JME); Epilepsy with generalized tonic-clonic seizures alone
GABRB1 and NEUROD4	gamma-aminobutyric acid type A receptor subunit beta1	neuronal differentiation 4	Signaling by ERBB4 GABA receptor activation GABA receptor activation		Lorazepam Ethchlorvynol Enflurane Temazepam Temazepam Butabarbital Butalbital Topiramate Etomidate Talbutal Pentobarbital Olanzapine Clobazam Meprobamate Eszopiclone Alprazolam Lindane Metharbital Chlordiazepoxide Amoxapine Adinazolam Clorazepate Acamprosate Midazolam Flurazepam Isoflurane Primidone Halazepam Halazepam Propofol Diazepam Diazepam Oxazepam Oxazepam Triazolam Triazolam Ethanol Methoxyflurane Ergoloid mesylate Clonazepam Methyprylon Halothane Desflurane Flumazenil Estazolam Estazolam Sevoflurane Glutethimide Gamma Hydroxybutyric Acid Bromazepam Clotiazepam Fludiazepam Ketazolam Prazepam Prazepam Quazepam Quazepam Cinolazepam Nitrazepam Prasterone Taurine Stiripentol Thiocolchicoside
GABRG2 and GABARAP	gamma-aminobutyric acid type A receptor subunit gamma2	GABA type A receptor-associated protein	Signaling by ERBB4 GABA receptor activation GABA receptor activation	Macroautophagy TBC/RABGAPs	Lorazepam Ethchlorvynol Enflurane Temazepam Temazepam Butabarbital Butalbital Topiramate Etomidate Talbutal Pentobarbital Olanzapine Clobazam Meprobamate Carisoprodol Eszopiclone Alprazolam Zolpidem Metharbital Chlordiazepoxide Amoxapine Adinazolam Clorazepate Acamprosate Midazolam Flurazepam Isoflurane Primidone Halazepam Halazepam Propofol Diazepam Diazepam Oxazepam Oxazepam Triazolam Triazolam Methoxyflurane Ergoloid mesylate Clonazepam Methyprylon Halothane Desflurane Flumazenil Flumazenil Estazolam Estazolam Sevoflurane Ginkgo biloba Glutethimide Flunitrazepam Bromazepam Clotiazepam Fludiazepam Prazepam Prazepam Quazepam Quazepam Cinolazepam Nitrazepam Prasterone Taurine Adipiplon Stiripentol Etizolam Thiocolchicoside Muscimol Lormetazepam		Febrile seizures, including: Febrile convulsions; Generalized epilepsy with febrile seizure plus (GEFS+); Dravet syndrome/ Severe myoclonic epilepsy in infancy (SMEI) Idiopathic generalied epilepsies (IGEs), including: Childhood absence epilepsy (CAE); Juvenile absence epilepsy (JAE); Juvenile myoclonic epilepsy (JME); Epilepsy with generalized tonic-clonic seizures alone

Search Results for: Influenza